Total Payments
$6,937
2024 Payments
$1,440
Companies
63
Transactions
333
Medicare Patients
900
Medicare Billing
$129,931
Payment Breakdown by Category
Food & Beverage$6,248 (90.1%)
Education$688.89 (9.9%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $6,248 | 321 | 90.1% |
| Education | $688.89 | 12 | 9.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $729.06 | 44 | $0 (2024) |
| Merck Sharp & Dohme LLC | $464.38 | 29 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $412.67 | 21 | $0 (2024) |
| Amgen Inc. | $362.79 | 18 | $0 (2022) |
| Daiichi Sankyo Inc. | $354.74 | 10 | $0 (2024) |
| Incyte Corporation | $337.03 | 13 | $0 (2024) |
| Genentech USA, Inc. | $248.13 | 15 | $0 (2024) |
| Gilead Sciences, Inc. | $223.83 | 9 | $0 (2024) |
| Janssen Biotech, Inc. | $219.08 | 11 | $0 (2024) |
| TESARO, Inc. | $194.16 | 7 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,440 | 55 | Daiichi Sankyo Inc. ($286.60) |
| 2023 | $859.11 | 35 | SANOFI-AVENTIS U.S. LLC ($99.95) |
| 2022 | $831.17 | 32 | Seagen Inc. ($118.31) |
| 2021 | $467.73 | 20 | GlaxoSmithKline, LLC. ($137.52) |
| 2020 | $242.75 | 16 | Astellas Pharma US Inc ($42.23) |
| 2019 | $1,120 | 60 | Merck Sharp & Dohme Corporation ($158.39) |
| 2018 | $926.23 | 50 | Novartis Pharmaceuticals Corporation ($137.58) |
| 2017 | $1,050 | 65 | Novartis Pharmaceuticals Corporation ($169.42) |
All Payment Transactions
333 individual payment records from CMS Open Payments — Page 1 of 14
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/14/2024 | PFIZER INC. | XTANDI (Drug), ORGOVYX, TALZENNA | Food and Beverage | In-kind items and services | $17.55 | General |
| Category: ONCOLOGY | ||||||
| 11/07/2024 | GlaxoSmithKline, LLC. | ZEJULA (Drug), JEMPERLI | Food and Beverage | In-kind items and services | $24.94 | General |
| Category: ONCOLOGY | ||||||
| 10/30/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $28.75 | General |
| Category: ONCOLOGY | ||||||
| 10/21/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $24.43 | General |
| Category: Hematology/Oncology | ||||||
| 10/10/2024 | E.R. Squibb & Sons, L.L.C. | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $99.68 | General |
| Category: Hematology | ||||||
| 10/10/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $22.85 | General |
| Category: Oncology | ||||||
| 10/03/2024 | Genentech USA, Inc. | Columvi (Biological), Lunsumio, Polivy | Food and Beverage | In-kind items and services | $20.80 | General |
| Category: BioOncology | ||||||
| 10/02/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $21.73 | General |
| Category: Hematology | ||||||
| 09/26/2024 | Fresenius Kabi USA, LLC | Stimufend (Biological) | Food and Beverage | In-kind items and services | $18.86 | General |
| Category: Biosimilars | ||||||
| 09/19/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $32.84 | General |
| 09/12/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI, TUKYSA | Food and Beverage | In-kind items and services | $29.57 | General |
| Category: ONCOLOGY | ||||||
| 09/05/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $19.16 | General |
| 09/04/2024 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | Food and Beverage | In-kind items and services | $25.18 | General |
| Category: HORMONE THERAPY | ||||||
| 08/28/2024 | Genentech USA, Inc. | Columvi (Biological), Lunsumio, Polivy | Food and Beverage | In-kind items and services | $22.76 | General |
| Category: BioOncology | ||||||
| 08/22/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $26.44 | General |
| Category: Oncology | ||||||
| 08/21/2024 | Janssen Biotech, Inc. | TECVAYLI (Biological), TALVEY, DARZALEX | Food and Beverage | In-kind items and services | $16.83 | General |
| Category: Oncology | ||||||
| 08/15/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $15.77 | General |
| Category: Oncology | ||||||
| 08/08/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $99.74 | General |
| Category: ONCOLOGY | ||||||
| 08/08/2024 | Pharmacosmos Therapeutics Inc. | COSELA (Drug) | Food and Beverage | In-kind items and services | $21.90 | General |
| Category: HEMATOLOGY | ||||||
| 08/08/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $8.45 | General |
| Category: ONCOLOGY | ||||||
| 08/01/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $30.71 | General |
| Category: Oncology | ||||||
| 07/30/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $15.65 | General |
| Category: Hematology | ||||||
| 07/18/2024 | GENZYME CORPORATION | ENJAYMO (Biological), CABLIVI | Food and Beverage | In-kind items and services | $35.72 | General |
| Category: Hematology | ||||||
| 07/16/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $22.07 | General |
| 07/11/2024 | TAIHO ONCOLOGY, INC. | LONSURF (Drug), INQOVI | Food and Beverage | In-kind items and services | $21.43 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 187 | 480 | $79,628 | $36,199 |
| 2022 | 4 | 174 | 442 | $70,343 | $34,827 |
| 2021 | 5 | 155 | 277 | $46,753 | $23,553 |
| 2020 | 6 | 384 | 556 | $155,866 | $35,352 |
Total Patients
900
Total Services
1,755
Medicare Billing
$129,931
Procedure Codes
20
All Medicare Procedures & Services
20 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 120 | 405 | $61,149 | $28,214 | 46.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 41 | 41 | $12,934 | $5,069 | 39.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 15 | 21 | $4,296 | $2,269 | 52.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 11 | 13 | $1,249 | $647.92 | 51.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 84 | 333 | $47,728 | $23,956 | 50.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 49 | 50 | $14,580 | $6,504 | 44.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 14 | 26 | $4,996 | $2,698 | 54.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 27 | 33 | $3,039 | $1,669 | 54.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 64 | 178 | $25,194 | $13,134 | 52.1% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 39 | 39 | $11,319 | $5,397 | 47.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 11 | 18 | $3,348 | $2,021 | 60.4% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 22 | 22 | $5,132 | $1,968 | 38.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 19 | 20 | $1,760 | $1,034 | 58.7% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 90 | 172 | $68,972 | $14,751 | 21.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 106 | 154 | $42,196 | $9,196 | 21.8% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 36 | 36 | $19,764 | $4,755 | 24.1% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 76 | 99 | $13,984 | $3,275 | 23.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 23 | 34 | $7,249 | $2,175 | 30.0% |
| 99211 | Established patient office or other outpatient visit, typically 5 minutes | Office | 2020 | 30 | 38 | $1,748 | $866.91 | 49.6% |
| 99212 | Established patient office or other outpatient visit, typically 10 minutes | Office | 2020 | 23 | 23 | $1,953 | $332.60 | 17.0% |
About Dr. Regine Leconte, M.D
Dr. Regine Leconte, M.D is a Hematology & Oncology healthcare provider based in Joplin, Missouri. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/19/2007. The National Provider Identifier (NPI) number assigned to this provider is 1831242031.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Regine Leconte, M.D has received a total of $6,937 in payments from pharmaceutical and medical device companies, with $1,440 received in 2024. These payments were reported across 333 transactions from 63 companies. The most common payment nature is "Food and Beverage" ($6,248).
As a Medicare-enrolled provider, Leconte has provided services to 900 Medicare beneficiaries, totaling 1,755 services with total Medicare billing of $129,931. Data is available for 4 years (2020–2023), covering 20 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology
- Location Joplin, MO
- Active Since 01/19/2007
- Last Updated 11/09/2022
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1831242031
Products in Payments
- KEYTRUDA (Biological) $401.70
- Enhertu (Drug) $265.49
- ZEJULA (Drug) $219.10
- OPDIVO (Biological) $202.06
- REBLOZYL (Biological) $172.52
- KISQALI (Drug) $158.94
- Lenvima (Drug) $152.71
- BLENREP (Biological) $137.52
- JAKAFI (Drug) $132.69
- Trodelvy (Drug) $129.86
- Imbruvica (Drug) $114.85
- DARZALEX (Biological) $114.56
- PROMACTA (Drug) $103.38
- Stivarga (Drug) $102.50
- ELITEK (Biological) $99.95
- LIBTAYO (Biological) $93.30
- TASIGNA (Drug) $89.56
- NINLARO (Drug) $89.47
- INJECTAFER (Drug) $89.25
- Orserdu (Drug) $77.54
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Joplin
Dr. Anisa Hassan, M.d, M.D
Hematology & Oncology — Payments: $14,208
Hematology & Oncology $14,208
Matthew Miller, D.o, D.O
Hematology & Oncology — Payments: $7,036
Hematology & Oncology $7,036
Dr. Kerry Williams-Wuch, M.d, M.D
Hematology & Oncology — Payments: $3,800
Hematology & Oncology $3,800
Samir Dalia, Md, MD
Hematology & Oncology — Payments: $3,276
Hematology & Oncology $3,276
Amir Anis
Hematology & Oncology — Payments: $3,158
Hematology & Oncology $3,158
Dr. Pamela Landon, M.d, M.D
Hematology & Oncology — Payments: $2,717
Hematology & Oncology $2,717